Company Human Genome Sciences
Equities
US4449031081
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2012 | Actelion Ltd : Exclusive: Human Genome rejected Amgen's $7 billion bid in 2010: sources | RE |
2012 | BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion | RE |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 200,202,597 | 199,790,772 ( 99.79 %) | 0 | 99.79 % |
Sector
1st Jan change | Capi. | |
---|---|---|
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B |
- Stock Market
- Equities
- Stock
- Company Human Genome Sciences